JP2024517738A - 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 - Google Patents

新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 Download PDF

Info

Publication number
JP2024517738A
JP2024517738A JP2023566493A JP2023566493A JP2024517738A JP 2024517738 A JP2024517738 A JP 2024517738A JP 2023566493 A JP2023566493 A JP 2023566493A JP 2023566493 A JP2023566493 A JP 2023566493A JP 2024517738 A JP2024517738 A JP 2024517738A
Authority
JP
Japan
Prior art keywords
dmt
minutes
composition
disorder
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517738A5 (https=
JPWO2022232179A5 (https=
Inventor
グレン ショート，
シリニバス ラオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of JP2024517738A publication Critical patent/JP2024517738A/ja
Publication of JP2024517738A5 publication Critical patent/JP2024517738A5/ja
Publication of JPWO2022232179A5 publication Critical patent/JPWO2022232179A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023566493A 2021-04-26 2022-04-26 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 Pending JP2024517738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
US63/179,679 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (3)

Publication Number Publication Date
JP2024517738A true JP2024517738A (ja) 2024-04-23
JP2024517738A5 JP2024517738A5 (https=) 2025-05-07
JPWO2022232179A5 JPWO2022232179A5 (https=) 2025-05-07

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566493A Pending JP2024517738A (ja) 2021-04-26 2022-04-26 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法

Country Status (12)

Country Link
US (1) US11602521B2 (https=)
EP (1) EP4329879A4 (https=)
JP (1) JP2024517738A (https=)
KR (1) KR20240000516A (https=)
CN (1) CN117320711A (https=)
AU (1) AU2022267240A1 (https=)
BR (1) BR112023022195A2 (https=)
CA (1) CA3216889A1 (https=)
CL (1) CL2023003191A1 (https=)
IL (1) IL308074A (https=)
MX (1) MX2023012651A (https=)
WO (1) WO2022232179A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
IL308816A (en) * 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
KR20250005175A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 양극성 장애의 치료를 위한 5-meo-dtm
CA3267555A1 (en) * 2022-10-26 2024-05-02 Atai Therapeutics, Inc. Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
AU2024242138A1 (en) 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
WO2025054397A1 (en) * 2023-09-08 2025-03-13 Atai Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) * 2023-10-02 2025-04-10 Atai Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
JP2023509132A (ja) * 2019-12-31 2023-03-07 ティーエフ テック ベンチャーズ 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法
JP2023530493A (ja) * 2020-06-22 2023-07-18 ユニバーシティー オブ チューリッヒ Ｎ，ｎ－ジメチルトリプタミンとハルミンとを含む組成物およびキット・オブ・パーツならびに治療におけるそれらの使用
JP2023537574A (ja) * 2020-08-05 2023-09-04 ユニヴェルシテートスピタル バーゼル Ｄｍｔ補助心理療法のための静脈内ｄｍｔ投与方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
EP4353314A3 (en) 2019-02-22 2024-07-03 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020169851A1 (en) * 2019-02-22 2020-08-27 Gh Research Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
JP2023509132A (ja) * 2019-12-31 2023-03-07 ティーエフ テック ベンチャーズ 口内溶解性フィルムおよび口内溶解性フィルムを製造し、使用する方法
JP2023530493A (ja) * 2020-06-22 2023-07-18 ユニバーシティー オブ チューリッヒ Ｎ，ｎ－ジメチルトリプタミンとハルミンとを含む組成物およびキット・オブ・パーツならびに治療におけるそれらの使用
JP2023537574A (ja) * 2020-08-05 2023-09-04 ユニヴェルシテートスピタル バーゼル Ｄｍｔ補助心理療法のための静脈内ｄｍｔ投与方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS OMEGA, vol. 5, no. 49, JPN6026014020, 2020, pages 32067 - 32075, ISSN: 0005836400 *
FRONTIERS IN PHARMACOLOGY, vol. 7, no. 211, JPN6026014019, 2016, pages 1 - 11, ISSN: 0005836399 *

Also Published As

Publication number Publication date
WO2022232179A1 (en) 2022-11-03
US20220339139A1 (en) 2022-10-27
CL2023003191A1 (es) 2024-04-01
CN117320711A (zh) 2023-12-29
KR20240000516A (ko) 2024-01-02
BR112023022195A2 (pt) 2024-01-16
WO2022232179A9 (en) 2023-07-13
IL308074A (en) 2023-12-01
EP4329879A4 (en) 2025-04-09
AU2022267240A1 (en) 2023-11-23
US11602521B2 (en) 2023-03-14
CA3216889A1 (en) 2022-11-03
EP4329879A1 (en) 2024-03-06
MX2023012651A (es) 2023-11-06

Similar Documents

Publication Publication Date Title
US11602521B2 (en) N,N-dimethyltryptamine compositions and methods
CA3182156A1 (en) Novel compositions of matter and pharmaceutical compositions
US12378194B2 (en) N, n-dimethyltryptamine salts and crystalline salt forms
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
JP3511074B2 (ja) ニコチン依存症治療のための薬学的処方
IL154041A (en) Nozzle spray for the transfer of a pharmaceutical preparation containing fentanyl salt and the use of fentanyl salt for the preparation of a medicine
KR20130135296A (ko) 베포타스틴 조성물
WO2016007729A1 (en) Co-packaged drug products
EP3538189A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
JP2011515485A (ja) ロフェキシジンを経粘膜送達するための組成物およびその方法
WO2025170990A1 (en) Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
WO2025054397A9 (en) Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025076151A1 (en) N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
KR20260013222A (ko) 트립타민 유도체를 함유하는 제제 및 그의 용도
WO2025024637A1 (en) Compositions for limiting sympathomimetic effects of psychedelic therapeutics
AU2002361709A1 (en) Analgesic delivery systems and methods of use
JP2003520237A (ja) 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
RS60554B1 (sr) Intranazalna kompozicija koja sadrži betahistin
JP2024531685A (ja) 神経障害の処置
US20260116853A1 (en) New n,n-dimethyltryptamine salts and crystalline salt forms
EP4338740A1 (en) A transdermal patch for promoting or accelerating myelination and/or remyelination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408